Evidence map›Paper›PMID 36791388›Full record

ArticleChembiochem : a European journal of chemical biology2023

Investigation of Sequence-Penetration Relationships of Antisense Oligonucleotides.

Nefeli Batistatou, Joshua A Kritzer

Open access · greenAbstract read
In one paragraph

Article in Chembiochem : a European journal of chemical biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Nefeli BatistatouDepartment of Chemistry, Tufts University, Medford, Massachusetts, 02155, USA.
Joshua A KritzerDepartment of Chemistry, Tufts University, Medford, Massachusetts, 02155, USA.ORCID 0000-0003-2878-6781
Tufts University · US

Funding

Diversity Supplement for Imani McDonald - Developing Autophagy-Targeting Chimeras and Optimizing Cell Penetration of Large-Molecule TherapeuticsR35GM148407 · NIGMS · TUFTS UNIVERSITY MEDFORD · PI Joshua A Kritzer · 2023 to 2026
$2.6M
Cell Penetration Profiling for BiotherapeuticsR01GM127585 · NIGMS · TUFTS UNIVERSITY MEDFORD · PI KRITZER, JOSHUA A · 2018 to 2022
$1.6M
NIGMS NIH HHS R01 GM127585NIGMS NIH HHS R35 GM148407
6 · The paper itself

Abstract

A major limitation for the development of more effective oligonucleotide therapeutics has been a lack of understanding of their penetration into the cytosol. While prior work has shown how backbone modifications affect cytosolic penetration, it is unclear how cytosolic penetration is affected by other features including base composition, base sequence, length, and degree of secondary structure. We have applied the chloroalkane penetration assay, which exclusively reports on material that reaches the cytosol, to investigate the effects of these characteristics on the cytosolic uptake of druglike oligonucleotides. We found that base composition and base sequence had moderate effects, while length did not correlate directly with the degree of cytosolic penetration. Investigating further, we found that the degree of secondary structure had the largest and most predictable correlations with cytosolic penetration. These methods and observations add a layer of design for maximizing the efficacy of new oligonucleotide therapeutics.

Indexed as

OligonucleotidesOligonucleotides, AntisenseBiological TransportCytosolOligonucleotidesOligonucleotides, Antisenseantisense oligonucleotidescell penetrationdrug deliveryHaloTagsecondary structure

Identifiers

PMID36791388
PMCPMC10305730
OpenAlexW4320892397

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.